0:00 Okay, we can start. 0:02 You can hear me? Excellent. 0:04 So welcome to Ground Truths. 0:06 This has been a podcast and a newsletter for about three years. 0:12 It's free, so there's nothing paywalled, and we have lots of fun podcasts. 0:19 I've been looking forward to this one for quite a while. 0:22 And that's because over the last couple of years, I got to know Jo Chikwe, who is a renowned cardiac surgeon. 0:30 She heads up cardiac surgery at Cedars-Sinai. 0:34 She is the editor of the Annals of Thoracic Surgery, which is the number one prestigious journal in the field, and a whole lot of other things. 0:42 So welcome, Jo. 0:43 Thank you, Eric. 0:45 Yeah, so this is... 0:47 A very extraordinary person who I want to start. 0:50 I haven't been to the American Heart Association for 16 years. 0:54 But a couple of years ago, she started working me over. 0:57 And she said, OK, so I'm coming. 1:00 So that's why I'm here this year. 1:02 And that's why we're having this chance to have this conversation together. 1:07 So first, I want to go a bit on your early background, Joe, because it's pretty extraordinary. 1:15 You had parents, your father from Nigeria, your mother from a Welsh coal mining town. 1:23 You grew up in Birmingham, England. 1:26 What's it like to grow up in Birmingham, England? 1:29 Well, weird when your father's Nigerian, obviously first-generation immigrant, and your mother essentially married him to sort of A, prove a point. 1:45 And I would say that Birmingham has a terrible reputation in England. 1:50 As soon as you open your mouth, most people think your IQ is about 30 points lower than it actually is. 1:55 But it's a wonderful, warm, and friendly place, and a place where it was very easy to get a good education. 2:03 It's an industrial city. 2:04 It's an industrial city. 2:05 It was the sort of heart of the Victorian industrial heartlands. 2:10 It's also the center of chocolate in the United Kingdom. Oh, I didn't know that. 2:14 Yes. 2:15 Cabris is headquartered there. Oh, wow. 2:18 But essentially, I left when I was about 16. 2:21 I'd already got a place at medical school. 2:23 I wanted to take two years out. 2:24 And originally, I thought that I might go and do some... 2:29 I'm not ready for that detour to Florence. 2:32 One thing before that, you're age six, and they ask you what do you want to do when you grow up, and you say I want to be a cardiac surgeon. 2:41 How did you know that at age six? 2:45 Who knows why a six-year-old wants to do what a six-year-old wants to do. 2:47 Did you have any relatives or anybody that was a model for you at age six? 2:52 No, no physicians in the family and nobody in my immediate family had gone to university. 2:57 But Magdi Yakub was a huge icon. 3:01 So that was an idol for you? 3:03 Probably the inspiration. 3:05 You know, it's kind of funny. A lot of people don't realize this. 3:08 The movie, you can see everything is very popular right now. 3:11 And Elizabeth Holmes, it wasn't in the movie, but they asked her when she was nine years old, what do you want to be when you grow up? 3:18 You know what she said? 3:20 A billionaire. 3:22 Now, this is quite the contrast because she actually became a cardiac surgeon, one of the most eminent cardiac surgeons on the planet. 3:31 Now, now you're finishing high school and you take this two-year detour and Fine Arts in Florence, which is not typical for the person who is going to be a cardiac surgeon. 3:44 What prompted you to do that? 3:47 Again, kind of a parental guidance. 3:51 I had a very ambitious idea that I wanted to go and do Some kind of mission work, ideally somewhere close to where my father had grown up. 4:01 And he pointed out that I wasn't very good with spiders and I didn't really like hot weather. 4:05 So, you know, I wouldn't be a great fit for that. 4:08 And long story short, I've always loved art. 4:11 I was not a natural scientist. 4:13 I have huge respect for the scientists in this room. 4:20 I figured out that the epicenter of most of Western art was Florence, so I decided to go there for originally a year, but I loved it, so I stayed too. 4:31 And you became a painter? 4:34 My focus, I've always painted, I've always drawn, but my focus there was essentially, it's quattrocentile art, which is essentially 1300 to about 1450, and it's just the most amazing time in culture. 4:47 It's kind of a point at which People are literally digging up Roman statuary, really understanding classical anatomy, and they're learning things that have been lost in terms of how we depict spaces, humans, the world around us, and there's this resurgence of interest in art, 5:07 so it's wonderful. 5:09 And everywhere you walk in Florence, it's just right in front of you. 5:12 Yeah, no, it's extraordinary in how that influenced your career in a totally different domain. 5:19 So now we go through this remarkable lineage of education, Oxford and Cambridge and the Royal Brompton and with Sir Magdy Yacoub and other notable surgeons and you get this great training and somehow you decide you're going to come to the U.S. 5:41 What about staying in the UK? 5:43 What made you say come to the US? 5:46 Well, the original plan was to stay in the UK and just come to the US for one year. 5:51 A couple of reasons. 5:52 The main one was that I just thought I would get really great surgical training, and I did. 5:57 The training system here is completely different. 6:01 It was absolutely phenomenal. 6:02 And once you see what American healthcare can do at its best, it's very hard to go back to somewhere where It's a phenomenal universal healthcare model, but it doesn't allow you to excel at that level. 6:17 Yeah. 6:18 And you became, through the Mount Sinai, you eventually became the first woman cardiac surgeon at Mount Sinai. 6:30 So you kind of went up pretty quick. 6:32 And that was only the beginning of many firsts. 6:36 So you're there till 2019. 6:39 I know that you're also at Stony Brook. 6:40 Then you go to Ciner Sinai. 6:42 Which is a very big cardiac center and you've become the chair of cardiac surgery. 6:49 And you've done thousands of cardiac operations now, right? 6:53 You've done a lot of mitral valve, tricuspid valve repairs and you've done a lot of research about outcomes. 7:00 One thing I'm interested in is you are this PROMIS trial that compares the mitral valve clip A non-invasive percutaneous catheter approach to fixing the valve versus surgically repairing the valve, which is what you're known for everywhere. 7:18 So this is a randomized trial ongoing. 7:21 It's a randomized trial and it's a really, really important randomized trial. 7:26 So for those of you that know the heart space, obviously we've got four valves for listeners that are not necessarily cardiologists. 7:35 And traditionally the way to treat severe valve disease has been open heart surgery, big stenotomy, you go on pump, you know, you're in the hospital five days. 7:44 And the Huge technological adventures and innovation in our space have really been in the transcatheter field. 7:50 So cardiologists can place guide wires through the going and fix some of these valves in a similar or slightly different way. 7:56 And in the aortic valve, we had a series of trials that essentially showed that a transcatheter, this wire approach, was about equivalent in the short term. 8:06 And there has been this explosion at the same time in a transcatheter approach to the mitral valve without any compelling randomized evidence whatsoever. 8:15 And the only trial that was being run was essentially designed effectively for FDA approval. 8:23 So it had a really short term outcome and it wasn't really looking at the majority of patients that we see in the clinic. 8:29 So I thought it was really important to run a trial in the patients that we see in the clinic that are generally lower risk. 8:36 With a much longer out term and designed as a superiority trial. 8:40 And I would say about seven, eight years ago, everybody said that that was just a far out, extreme, unworkable, not feasible idea. 8:49 I would say huge kudos to, first of all, it was PCORI, who have a place, a randomized trial grant of about $26 billion that expressed interest in the trial. 9:01 They didn't commit to it, but they said it was an interesting idea. 9:04 And that letter of interest alone was enough to get the NHLBI and the Cardiothoracic Surgical Trials Network engaged. 9:13 And that network is the most phenomenal collaborative effort. 9:17 They've run six or seven trials in the cardiovascular space, all published at a high level. 9:22 And this was the first time they brought interventionists together with cardiac surgeons to design a trial, which we completed enrolment this July. 9:31 And we're really trying to figure out A, how we can report some outcomes early to at least maintain interest without compromising our results. 9:42 And I'm certainly very, very nervous. 9:44 It's a really important topic for me and I really do hope to goodness that the trial is well designed and that it also shows what I... 9:52 Suspect to be the truth, but it's going to be fascinating. 9:55 Yeah, it really is. 9:56 This is going to be one of the most watched trials of valvular heart disease because the cardiologists are all doing these clips and the surgeons are trying to do mitral valve repairs like Joe does them. 10:10 Our group at Scripps and I have referred patients to her because she is the regional guru for this. 10:17 And so we'll see how that trial winds up. 10:19 That'll be really interesting. 10:21 Now, in the country, my understanding is of all the cardiac surgeons, there's about 8% who are women, about 8%. 10:32 By the way, I read back a year ago, there was the Association of Annual Meeting of the Women in Thoracic Surgery, your people, right? 10:44 And this New York Times article covered this meeting. 10:49 And the quote was, Cardiothoracic surgery had a reputation which is fading, but probably not gone, as the toughest, meanest, and most macho specialty. 11:02 What do you think about that? 11:04 Which book? 11:07 Cardiology is a male-dominated, has been a male-dominated specialty, but surgery, much more, with 8%. 11:14 Now, let's drop down. 11:15 What's the percent of black women cardiac surgeons in the United States? 11:23 It's vanishingly low. 11:25 We tend to know each other. 11:27 Is there like a handful? 11:29 A handful. A handful. 11:30 I suspect a handful. 11:31 And it's not necessarily different. 11:33 Like, many of you are in areas where it's equally skewed in terms of broad representation, right? 11:41 Yeah. 11:43 But that's pretty extraordinary when you think about it. 11:46 Now, you know, I thought about last week when I saw Keisha Lance Bottoms become the first black woman governor ever in the United States. 11:59 And these things like FIRST, but just to go back on this, two years ago we had a total takedown of DEI. 12:08 What were you thinking about when this country was taken apart, became a bad word, you couldn't put it in grant applications? 12:15 If you did, you know, you could be penalized. 12:19 And in fact, I know colleagues who had it in their grants and they lost their grants or they wouldn't be submitted. 12:26 A lot was going on in these past couple of years to try to change the whole tide. 12:32 What were your thinking along those lines? 12:35 I think primarily that if you're a scientist or a patient or a clinician, what you want is the best possible outcome. 12:45 And the way that you get that is by ensuring that the pool of people from whom you select Is the broadest possible pool. 12:54 You don't restrict a pool to predominantly men or predominantly women. 12:58 You don't restrict it by race. 12:59 You don't ideally restrict it by geography. 13:01 And you don't restrict it by socioeconomic background. 13:05 You've got to broaden the pool. 13:07 And the shift that we saw was really problematic because you went from a place of People making assumptions that you're in a position because of being a diversity. 13:24 I've literally had, frankly, leadership look at me and say, oh, we thought you were the diversity hire, to now you're getting penalized because people in leadership no longer want to be seen as having diversity. 13:39 So it's somewhat discouraging. 13:43 That said... 13:45 The pendulum goes one way, the pendulum comes back, and all you can do is be the best that you can possibly be and just wait till the pendulum gets to the right spot. 13:54 That's a great answer. 13:56 I couldn't agree more. 13:57 And I like your patience for the pendulum to start to go back. 14:00 Well, I'm famous for my patience. 14:05 You are a really big inspirational force for your field, for your colleagues, of course, at Cedars-Sinai. 14:13 And you exemplify the just extraordinary qualities of leadership, mentorship. 14:21 And also at the same time patient care because I know from patients that I have that have seen you they felt like they were the only person in the world with you when you saw them and took care of them. 14:34 And that's what every patient would want. 14:36 So how do you do all this stuff? 14:38 How do you balance your, you know, trying to train the younger folks, inspire all your colleagues? 14:46 You work across the line between cardiologists and cardiac surgeons, as exemplified here. 14:52 How many cardiac surgeons are such a big part of the American Heart Association, which we'll talk about in a minute. 14:58 So how do you balance all this stuff? 15:01 You're making an assumption that I balance it Or balance it well and I don't. 15:06 I would say, speaking to training younger surgeons, that's a little bit like sitting in your brand new Ferrari in the passenger seat and handing the keys to an enthusiastic Person next door is even saying, here, have at it, have a go, and that Ferrari's actually a human being. 15:23 It is really, really hard to train, and it's so, so, so important. 15:30 And one of the things that's been an absolute joy at SEED is recruiting a group of faculty, and then subsequently residents, and effectively creating the residency program that I wish I could have trained at. 15:43 We have, I think, a completely unique and very different approach to training. 15:48 And our residents who don't know any other training environment usually often don't appreciate that until they go somewhere else and then they realize quite what we've And that team is pretty much the only thing that allows me to come away and do something like this. 16:05 I think this is so valuable. 16:09 The collective wisdom in this room, the collective wisdom at scientific sessions, this is such a unique meeting. 16:16 Everything from basic science all the way to health technology, that there is no other meeting in the cardiovascular space like this. 16:23 So it's been really important for me to try and contribute and To help maybe be a little bit of a different perspective. 16:32 That said, I went from saying I would never operate on the day that I was going to have to leave town to being very reliant on a really strong team. 16:43 And hand on heart, I know that the people that are at bedside can do a better job oftentimes than I can. 16:50 And that's the only thing that allows me to do this. 16:53 It's the teamwork. 16:54 Nothing else. 16:56 And I can imagine just what your team is like in the operating room team that probably just love to work with you and... 17:05 Unlike some of the cardiac surgeons I knew when I worked at Cleveland Clinic that would throw things and all sorts of bad things would happen. 17:12 I'm sure that doesn't happen in your operating room. 17:15 Now, when we talk about the training and you are really a role model for so many people, both locally and broadly, you touched on the American Heart Association because you have given now four years. 17:31 I didn't know this. 17:33 Four years to develop this program and now lead the sessions here. 17:38 That's a big commitment to the American Heart Association. 17:42 They didn't say it was going to be quite as big a commitment as it actually turned out to be when they asked me. 17:46 They said it's obviously about one hour a week and that sounded completely manageable. 17:51 Little did I know. It would not change a thing. 17:53 It's been an absolute joy. 17:56 I have learned so much. 17:57 To go from, we had a Nobel Prize, like while you were doing man versus machine, Josh Anguish, Nobel laureate in 101, was giving us instrumental variables. 18:07 He dissected the ischemia trial. 18:10 This time last year, it wasn't Josh Anguish. 18:12 It was Arden Pasapuchian talking about piezo crystals. 18:15 And to be able to go from that level of science to this level of application just in one space, it's just amazing. 18:24 Yeah, and Artem Patapuchin is one of my colleagues at SCIRF Research who, as Joe mentioned, discovered the piezo receptors, got the Nobel Prize, Nobel Prize, and these receptors are incredible. 18:36 They're everywhere and every biologic function you can imagine. 18:40 And it's great that the AHA started to have people like him that are not, and he told me he had a great experience, which is really nice. 18:49 You are also going to be on the board of directors of the American Horror Association for the next two years. 18:54 So you obviously are keen giving your time for this organization. 18:58 Can you give us kind of a sense of what does the AHA mean to you? 19:03 I think if you take home one thing from maybe today, it's this. 19:09 The AHA is so much more than what each of us sees in our own sort of interaction with it. 19:16 I had no idea that it essentially funded about $6.5 billion of research. 19:22 It's the largest funder outside of the NIH. 19:24 That's phenomenal. 19:25 In terms of education of both patients and healthcare physicians, it touches millions of lives. 19:31 It's got a global impact. 19:34 In terms of transforming just health, trying to make sure that the food we have access to, the Advocates for exercise, all of the basic things that our industrialized healthcare complex doesn't always do. 19:48 The American Heart Association is one of those rare organizations that's actually unbiased. 19:52 It's got a huge amount of academic and intellectual integrity. 19:56 So it's a really worthwhile organization to support. 20:00 It essentially writes our guidelines. 20:02 It drives some of our best evidence. 20:05 It fosters our early career scientists. 20:07 I mean, It's really difficult to articulate how important that is, particularly in this politicized, dynamic, transient, industry-driven landscape that we all exist within. 20:21 I was going to tell one quick story about how I got started with AHA. 20:26 I was a fellow at Johns Hopkins and applied for the local affiliate of Maryland to get an AHA grant. 20:36 While I had been at UCSF as a resident, That's when transthoracic echo, 2D echo, was getting going. 20:43 And also transesophageal echo. 20:48 So I saw some transesophageal echo at UCSF with Nelson Schiller. 20:53 And I asked about, you know, a probe. 20:56 And when I showed up to Baltimore, I got the folks, the company was then called Diastonics to give us a probe. 21:04 And I went to the operating room to meet with the cardiac surgeon and say, what do you think about us doing a project of putting the probe in and people like before surgery, after surgery, see what we can find. 21:14 And they looked at me like I was an alien. 21:16 You know, I came from another place. 21:18 And they said, okay, sure, why not? 21:20 And then I applied for the grant, and that was the very first grant I got, which was the AHA grant to basically fund my fellowship slot, which fellowship salary in 1982 was $12,000 a year, okay? 21:36 Anyway, I'm very grateful to the AHA because that's how I got started, and I think it's an incredible organization, and to have recruited you now for four years to do this program and two years more on the board, that says a lot. So... 21:49 I do want to go back to the operating for a second because at these meetings, a lot is about AI. 21:57 And I want to get your thoughts about how AI is going to influence cardiac surgery because we talk a lot about how it's going to influence the daily practice of medicine. Do you see it having a place in the OR before, going in, after? 22:12 How do you see that moving forward? 22:15 I think ultimately, it's going to have a huge role in the operating room. 22:19 When we do cardiac surgery, most of our cases, we need a heart-lung machine to take over the function of the heart and the lungs. 22:26 So essentially, you've got an individual running... 22:31 Full centrifugal pump circuit that's delivering oxygenated blood, sucking it out, oxygenating it, filtering it, cooling it. 22:40 And right now, generally, they set the parameters, they control it. 22:45 I don't know if, kids, you ever sat in a simulation in a, say, natural history museum where you got to run the body and within about 30 seconds of you sitting at the controls, the body was dead. 22:55 Perfusionists are very, very, very skilled at running things so that doesn't happen. 23:01 It's kind of ludicrous that a person's in control when it could be a real-time, AI, enhanced, responsive, dynamic process that's much, much safer. One. 23:16 Two, surgeons, we're fallible. 23:19 A lot of the reason we love surgery is this sort of intellectual... 23:23 I don't know, ego trip perhaps, that you're required to make these instant judgments and use art to figure out solutions to problems, but that's why it's imperfect. 23:33 And you could get much, much closer to perfect if you had AI-supported interpretation of images that could help you plan approach, could help you plan your procedure and help you guide outcomes. 23:46 And then finally on the ICU, we have all of our patients hooked up to real-time telemetry, and we are using that so, so, so poorly. 23:53 If we had, again, real-time AI-enhanced assessment of rhythm, electrolytes, temperature, physiological parameters, you could prevent atrial fibrillation. 24:05 You could prevent arrhythmias. 24:06 You could prevent a ton of the complications that cost us. 24:10 And the amazing thing about cardiac surgery is it's gone from a 50% mortality in Nina Bramwald's early days to a 0.5%. 24:20 I mean, you can't even... 24:21 I'm not going to say get your hip replaced for that, but it's so, so, so safe. 24:26 But you could probably do better than that and make it a death and almost never event in cardiac surgery and have patients recover really, really much more quickly than they do today if we did those things. 24:41 Yeah, I can imagine how every aspect of medicine has potential for transformation. 24:48 So we want to open it up to your questions. 24:52 And I think the floor is open. 24:56 We have some microphones. 24:57 And also ask Kim some questions. Oh, yeah. 24:59 Because I fully appreciate that 90% of you came here to hear what Dr. 25:04 Topol has to say about the areas in which you thrive and live and work. 25:11 And you can ask. You're free to anything you say. 25:13 I'm going to put you on the hot spot. 25:15 Open it up. 25:16 You get us started. Otherwise, this audience is going to be, yeah. 25:18 So there's a mic over there if you'd like to ask the question, and there is also one over there too. 25:25 Go ahead, please use the mic so we can hear you. That'd be great. 25:29 Yeah, there's a mic back there if you wanted to. 25:31 We really want to make it interactive. 25:34 Go ahead Joe and Eric thank you so much for this conversation. 25:41 It is interesting to me I've spent a couple of those years with Joe And thanks for asking the hard questions, Eric. 25:49 I think I've learned more in the last 30 minutes about her than I have in the last couple of years, especially about kind of your personal journey. 26:00 I'm really excited about the AI piece for sure, but I'm kind of curious how both of you think about the non-AI pieces of how medicine is being transformed, particularly around some of the genetic therapies that we're seeing just advance. 26:17 You know, Dr. 26:17 Topol, you know, I follow obviously your feeds on social media and you talk a lot about that. 26:25 I was wondering if you could just give a broad overview of how you're thinking about the future of medicine. 26:30 We, Joe and I can tell you like every year. 26:34 In the late-breaking sciences that get submitted to us, there's more and more of these ideas around targeted molecules, targeted therapies. 26:41 We did see the results recently, just yesterday, of some of those, but it just seems like it's coming at a faster and faster pace, and I just was wondering if you had some thoughts about that. 26:51 Yeah, I mean, this is an extraordinary area. 26:55 On Friday, Nature was published in vivo, In non-human primates, so not yet patients, but soon to start, basically knocking out the ANGPTL3 lipid gene, bringing down LDL cholesterol 50% durably for years. 27:20 And what does that mean? 27:21 Well, if that could be done because it's going to the liver, Getting gene editing in the heart is another challenge, which we're going to need help from surgery. 27:32 But if you're going to the liver and you're working on getting lipids down for life, imagine how that could someday, if it's inexpensive and practical, be the way we prevent atherosclerosis. 27:46 It's pretty exciting, but it has a long ways to go. 27:49 But on the other hand, there are a lot of diseases of the heart that because unlike the eye, Or the liver or the blood. 27:57 We have a delivery issue. 27:58 And there the question is, should we be thinking about moving the whole genome editing field, gene therapy field, by getting help with surgery, perhaps with minimally invasive surgery, to get better delivery so we can start to affect the inborn cardiac errors. 28:18 I don't know what you think about that. 28:19 I think it's certainly one avenue. 28:22 I feel that another avenue is thinking about how we use the opportunity of being inside a heart during surgery. 28:30 We have Caltech, which is on the doorstep of Cedars. 28:34 I remember having a joint collaboration with some of the engineers there, and the micro-sensors that they've developed would allow you to almost create a non-invasive ICU in terms of being able to detect real-time Hemodynamic 28:51 and physiological changes if you could just implant them in hearts at the time of surgery. 28:55 I noticed we had a question at the microphone. 28:58 Yeah. 29:00 Thank you and a wonderful session. 29:03 Nicola Stratton from Australia. 29:06 I'm a cardiac researcher, nurse, and an implementation scientist. 29:11 And one of the things that keeps me awake at night, we know in healthcare, 60% of the healthcare we deliver is in line with evidence, but probably around 40% is low-value care or some form of harm. 29:27 So in cardiology and medicine, what do you think we can do To de-implement low-value care, I sit with the tension of innovation in cardiology and a work in valvular heart disease versus there's so much stuff that doesn't work 29:44 or does harm. I'd love to hear your thoughts. Thank you. 29:47 Well, thanks for coming from Australia and your question. 29:52 Jo, among many things, she's done a lot of work to study outcomes. 29:56 So maybe you should give us some guidance on that. 29:59 I think you raise a really important question and I would also, and I'm not going to solve for it, I will make the problem bigger. 30:07 I think that the healthcare structures that we work in It's always about incentivizing activity and productivity, much less about prevention. 30:20 We're very good at treating advanced disease. 30:21 We get very excited about that. 30:23 We're definitely not as focused as we should be on population management. 30:27 And the care that we deliver is utterly fragmented. 30:30 It's so siloed, it's almost tribal. 30:34 One of the things that drives excellence in US healthcare, which is this kind of competitive entrepreneurial environment, also drives this completely fragmented healthcare. 30:43 It doesn't follow a patient longitudinally. 30:46 And what I don't want to do is sort of go back to an NHS, which is obviously where I trained and had a lot of strengths, broad model because the excellence is harder to get to, but the Advantage of the system like that is at least 31:00 that you have universal health care that is free at the point of delivery. 31:04 And I think somehow we've got to be able to deliver some kind of universal basic health care that is not dependent on employment, not dependent on your ability to pay for it. 31:17 Yeah, it's a tough one. 31:18 A great question. 31:19 Yes. 31:21 Hi, my name is Peter Park. 31:22 I'm a clinical scientist. 31:25 I have a question for both of you about AI. 31:28 I think we're all optimistic about AI delivering on more accurate information and helping us get to that target of perfection. 31:38 But the areas of AI that I worry about Is the ability to influence the content, just as we've seen in political narratives with with counter positions and then secondly. 31:54 Taking away some of the valuable physician-patient relationship aspects of care, if you're just looking for more and more information and trying to get AI to answer questions about care. 32:09 Do you have thoughts on those two challenges? 32:12 I think those are really important challenges. 32:14 And I don't know if you were able to go to Nate Gross' fireside chat yesterday. 32:19 So Nate Gross is the head of health at OpenAI. 32:22 And that question was posed to him broadly. 32:29 Our sources of information are always going to be biased, that there is almost an inherent bias. 32:34 It doesn't matter whether it's biased by the fact you're coming from a particular specialty with a particular slant, or individuals that ran the trial have come with a particular slant, The interpretation of them. 32:47 So you've sort of got to choose the bias. 32:49 He was very clear that one of the important aspects of using AI in this way is about how you force it to retrieve from data sets like PubMed and how you place guardrails in so that what you're retrieving is as unbiased as it can potentially be. 33:08 But clearly, clearly, there's going to be the opportunity and the ability to skew What it reports out. 33:15 But hopefully that will still be better if we do it right and we place the right guardrails in place than the biases inherent from a single physician with their evidence gaps, their knowledge gaps and their own personal biases. 33:31 And I would hope that that allows you to have a much more Personal conversation with a patient, instead of sitting over here typing away and trying to find the right window, perhaps the fact that it's listening to your dictation, 33:45 it's generating a note and just giving you the data points you need, allows you just to have that much more personal, real connection. 33:54 Yeah, I think your point is so important, but the trade-off of having information and more autonomy for patients As well as what Joe just described, which is keyboard liberation or the movement towards that, brings back a gift of time for important matters to be face to face 34:15 with real presence, real trust, real communication. 34:19 So if we can get there, we'll be making an extraordinary restoration of the patient-doctor relationship, which used to be there in the old days. 34:29 And I hope we can use AI to get it back. 34:31 But I did, your point made me think of another thing. 34:35 Joe is the editor in chief of a journal and journals are under considerable pressure now because articles are being submitted that are either written by AI or you can't tell. 34:48 How do you handle that now? 34:50 Maybe because the surgeons are not as much using AI in their composition or whatever, but have you encountered this problem? 34:57 So I don't think that it's the journals that are under pressure. 35:00 The entities that are under pressure are the publishers, right? 35:05 So when Elsevier and Lippincott Williams and others took away print, and we all went digital only, great for the environment, probably great for profit margins, they took away a barrier to entry in publishing. 35:19 So no longer did you need factories and forests and paper and lorries and trucks delivering it. 35:25 You've taken away a real barrier to entry. 35:28 If anybody has sat down or saw that 10-second video that I played yesterday, 35:35 there's almost no barrier to entry now in terms of you being able to disseminate research. 35:42 And I would ask myself, why would I as a university pay millions of dollars of subscriptions to have access to publications That I'm paying my employees to generate research for. 35:58 I think the publishers are very aware that as middlemen they could very easily be cut out of that equation. 36:05 You could go from the research to dissemination so much more quickly. 36:10 And the challenge is the quality control. 36:13 So as an editor it's actually always a joy to have a lot to choose from. 36:19 AI peer review is going to hopefully professionalize that process. 36:24 And in the same way as I would hope that the team next year use AI to do the labor of the slotting of tens of thousands of abstracts and use the human approach to really fine tune and really make it work better. 36:40 As a journal editor, I plan to use AI to do an initial peer review. 36:47 And use the editorial board just to add the expertise and the finesse it so that it's more efficient, more effective, and hopefully better quality. 36:59 Yeah, that's what's been striking is that recently there's been studies using AI peer review then judged by human experts in that field. 37:09 And the human experts deem the AI peer review better than the... 37:15 Okay, so the machine was better than the peers. 37:18 And that's actually probably good for an editor-in-chief because it's hard to find reviewers. 37:23 They're too busy. 37:25 It's much more sophisticated. 37:26 What you did last year, which was dump a manuscript into chat GPT and say, please generate a peer review. 37:32 And it would spit out some, you know... 37:37 Very smooth sounding tech bro waffle is not what it does this year. 37:42 This has improved so much in such a short time. 37:46 It's actually better now than about 80 to 90% of your peer reviews generated by humans. 37:54 You know, when I used to be part of the program development, we had paper on boards and we were putting in the sessions like that. 38:04 Is that still how it's done? Like a whiteboard? 38:07 Or is there a use of any AI? 38:09 So it's a long discussion. 38:12 And Justin Dennison, who is the VP of meetings and actually the grown-up in the room 99% of the time, is sort of the interface between definitely a move towards, I think we need AI to do a lot of the stuff that we've had a whole committee of people to do. 38:29 Even something as simple as tailoring your journey around the meeting. 38:34 Spend a Saturday coming up with a meeting program planner that would allow each individual one of you to just say, okay, these are things that I've sort of been interested in broadly, or this is what I've published on PubMed, and it would just give you an itinerary, 38:47 totally personalized, so you wouldn't have to spend, frankly, any time trying to figure out what's on the app or what am I missing. 38:53 So done right, it can really improve your meeting experience, and done right, it can really help journals well. 38:59 When I say it democratizes research, yes, we're under a tsunami of clinical outcomes, large dataset, stuff generated by AI. 39:07 I think what it does, though, is highlights what AI can't do yet. 39:12 So what AI can't yet do is clinical trials. 39:15 It can't do great translational research. 39:18 And it can't provide true, true expert opinion. 39:21 And I think that's where clinical journals probably will focus. 39:26 You've got another question on the microphone? 39:29 Do we have, were you up there first, and then we'll go over to you. Go ahead. 39:31 There's loads of people. 39:33 Dr. Chikwe, thank you for your contributions and sharing your journey with us. 39:38 I didn't know you were at Mount Sinai when you first came to this country, but I'm quite familiar with David Adams' work and with Dr. 39:46 Anyanu's work in mitral valve repair. 39:50 So I know you are well qualified. 39:53 Thank you. 39:54 But I'm particularly struck by what you said about why you stayed in the United States after you came for that first year. 40:06 And I have talked to, when you said that there were opportunities here for you as a surgeon that you didn't think the UK could offer, if I understood you correctly. 40:18 Now, I've talked to a lot of internists at international meetings like this one, Who are from Britain. 40:25 And they said they couldn't see health care being administered any other way but the UK system with the National Health Service. 40:33 So my question is, as we just had an election here two, you know, three days ago. 40:40 Okay. 40:42 Dr. Topol's already mentioned what the prior election did for DEI. 40:46 But now, as you know, there are a lot of Parts of the country and recently elected politicians who are now going to have some power who are clamoring for national health service in this country. 41:04 Some call it Medicare for all and whatnot. 41:06 So obviously we could talk all afternoon on this, but if you give us your quick take on what you saw in Britain, because if America moves to a Medicare for all, What you think are the pros and cons and bullet lists from what you see 41:23 about the National Health Service and the way healthcare is provided in Britain and what we might expect with a Medicare for All here in the United States and how that would influence medical practice. 41:34 I suspect the NHS is not the right model to use as a comparison. 41:39 Britain's a much smaller country. 41:41 It would be like a state. 41:43 And maybe you look at the states that you have, like Massachusetts, like Maryland, like Vermont, that are already doing some kind of model that's a little closer and figure out what works in the US. 41:56 But broadly, the goal, in my humble opinion, is... 42:02 Some form of universal health care coverage. 42:04 And it might be basic, but it should apply to everybody. 42:07 And you can then figure out how you fund the more invasive, more complex, more expensive care. 42:16 But universal health care, it should be a utility, a basic human right. 42:24 We have folks here from the UK. 42:27 It was interesting because I did a review of the NHS 20... 42:33 18, 19, and I would just walk around and say to people on the street, what's your sense about the NHS? 42:41 And it was the most highly revered, more than the BBC, more than the royal family. 42:49 I don't know what it's like now because the funding has just gone down so much, but it has been a model, which I think, as you say, Joe, it would not be transferable, but the idea that every citizen It's a human right, 43:05 civil right, to have health care, and the UK has shown that that can work, even in strained times, right? 43:13 Go ahead. 43:14 Yeah, and then we'll go over to you next, okay? 43:17 Thank you. David Alter from Toronto, cardiologist, population health scientist. 43:21 Loved your journey and talk. 43:25 And I loved as you were getting into kind of how you're adapting cardiac surgery in your training program, For the new generations. 43:34 And I remember back in the day where there's still like a lot of divisiveness. 43:40 I know we don't practice that way. 43:41 We don't say we, but the cardiologists are on this side of the room. 43:45 Surgeons are on this side. 43:46 When you look at the trends of surgery over the last, you know, 10, 20 years, they're declining. 43:52 So my question really is in that context, Recognizing where the future is going, how are you as a leader for 10 years down the line, what is the job to be done for a cardiac surgeon when we have all of this vacancy rate in doctors, cardiologists, primary care, 44:16 all this stuff that we need in human resources? 44:18 Where do you think cardiac surgery in 10, 15 years is going to do? 44:22 Is it going to fill that void? 44:24 Are you going to be doing new procedures on different organs or different cells? 44:29 I'd be interested in your thoughts. 44:30 So I think it was Joseph Hill yesterday that kind of introduced his question to us with the Patrick Sorois award lecture by saying, you know, cardiac surgery, it's going to be obsolete. 44:44 You're going to be out of a job. 44:47 And my view is that's a very... 44:50 Narrow view of the complexity of the human body and pathology and the capability of pathology to exceed pretty much any technological approach that you've got, that there will probably always be some form of role for cardiac surgery. 45:06 And right now, the residency applications are just like that. 45:12 We have, you know, it's basically about 100 per slot people applying, and they are phenomenal. 45:18 They're just incredible. 45:20 Really, really stellar applicants. 45:22 So my job is to really just to not put them off and try and give them a great training platform. 45:28 And I see, is that Melinda Sy from Cleveland Clinic standing at the back there? 45:33 You ask about how do you make it more collaborative between Cardiology and cardiac surgery, I would say his institution is just the absolute emblem of that. 45:43 So, yes, I think there are models of how to do it really, really well out there. 45:49 And that's essentially what's the right thing to do for our patients, because ultimately that's really why we're all here. 45:57 I'm Kenton Gregory, a cardiologist out of Portland, Oregon. 46:02 I've been leading a large effort in medical AI development for the past 10 years. 46:08 What I see, what I worry about, what I fear is less about bias, which is a real concern, but more about physician clinical skill downscaling. 46:21 And my question to you is how can we prevent that? 46:24 And it's going to hit is happening. 46:26 And how we can mitigate that and actually use AI for physician clinical upskilling. 46:35 Yeah, this is a great issue right now which transcends education, no less medicine. 46:42 The issue of de-skilling, never skilling. 46:46 We saw a study in GI endoscopy where when the AI was withdrawn, the ability to pick up things was reduced because of reliance on AI. 46:58 And is this going to get worse over time? 47:00 And it's a real concern. 47:02 Especially for the young folks coming through this never-skilling group. 47:06 So we have to really take this seriously. 47:10 It's different for surgeons that are operating on a frequent basis. 47:15 That isn't really going to challenge their skilling. 47:17 But for our cognitive aspects, the ability to reject the AI recommendations, diagnosis, treatment plan, we have this problem with Trusting AI too much or automation bias that, oh, it's AI, it's got to be wrong. 47:38 So we have a lot of unsteadiness right now. 47:40 We're in this kind of midst of a very awkward time. 47:47 But I do think if we don't concentrate on preempting the de-skilling, never-skilling, we've got trouble. 47:54 So I'm so glad you brought that up. 47:56 Any thoughts about that, Jo? 47:59 I think you said it all. 48:00 Okay, thank you. 48:02 Anyway, over here. 48:04 Hi, I'm a cardiologist in the Essex Cardiothrastic Center. 48:08 And you very clearly, to follow on from the question before, you very clearly said you'd like more universal coverage in the United States system. 48:18 But I'd be curious to know what advice you would give to the NHS as to how that may adapt and evolve for the future. 48:26 There's a feeling that it's struggling at the moment. 48:28 And if you could suggest one or two changes to the NHS system to make it better. 48:41 Probably investment. 48:42 You run it very lean. 48:44 And the times when it's thrived, it's just had a ton of investment. 48:49 I think the spend on US healthcare is about 18% of GDP. 48:55 I think the NHS is... 48:57 Maybe hovering around 12, 13, 14 percent. 49:01 So I suspect a percentile up would make an absolutely profound difference. 49:06 But some of the best hospitals in London and sorry, Merlin and Cleveland Clinic aside at the NHS hospitals, that's where everybody right now would go for the highest level care, brand new. 49:21 Phenomenal. 49:22 The best academics, the best quality of care, it's within the NHS. 49:28 It's just from my personal insight to this, Magda Yacoub was a very special guy. 49:34 Terence English was a very special guy. 49:36 David Weatherall in Oxford, who I was a student with, one of the most brilliant minds. 49:42 So there are... 49:44 Some of this doesn't depend on the money. 49:46 Something about the culture of how you run. 49:47 Some of it doesn't. You're right. It depends on the culture. 49:49 But one of the reasons I stayed in the U.S. 49:51 was there was such a greater respect and investment and energy around academic medicine in the U.S. than I ever saw in the U.K. 50:02 So that would be the other area to focus on. 50:04 You've got to foster the academics. 50:06 I would just comment. 50:07 So when Jeremy Hunt, He recruited me to do the NHS review. 50:13 His vision was that could AI technology stop the extraordinary workforce expansion, which I think you know in this country, this is where all the new jobs are in healthcare. 50:30 And around the world, certainly all the high income countries, this is what's really leading to terrible economic stress. 50:40 I think he actually had it right, and the question is, can we use AI to reduce this, the growth is unchecked. 50:49 As the populations get older and more complex, the burden for clinicians just increases and you just can't keep hiring because this is the number one line item, whether it's in hospitals, whether it's outpatient, whatever it is, and we can't keep up. 51:08 That's where we really, you know, everyone talks about the fears of AI, but we haven't thought about more the big picture of how AI could rescue a situation. 51:18 And I actually think the NHS could become the model country implementing AI. 51:23 There's a lot of real talent there, and it's also out of need. 51:28 At a desperate need and they hopefully can show us the way because we're not likely to do that here without universal care that's available. 51:39 One last question. 51:43 Go ahead. 51:45 Thanks, Eric and Joe. 51:48 To the comment regarding, I'm Malin Desai from Cleveland Clinic. 51:52 Joe, surgery and cardiology is not competition. 51:56 It is complementary in 2026 and beyond. 51:59 It never was. 52:00 Question for Eric. 52:03 In light of the fireworks yesterday in the opening session with the negative trial, especially the anti-inflammatory trial, do you think rather than recruiting people en masse, should there, in your opinion, if you had to redo this again, should there be another checkpoint 52:24 where you measure inflammation around the coronary wall or somewhere? 52:33 Not systemic inflammation, but targeted inflammation, and then recruit these. 52:38 Yeah. 52:39 Your thoughts. 52:39 You are spot on with that. 52:41 If I could, having learned what we did with those two trials, going backward, the ideal thing and what we can do now is to only test these interventions in people who have clear-cut coronary inflammation, which we can image now. 52:57 And we can also look at organ clocks like the heart. 53:02 And the artery clocks to be sure that they're deviating and it's some abnormality. 53:07 So we can do things now to scout out whether it's likely, before doing a 10,000 patient trial and spending hundreds of millions of dollars, whether it's going to work. 53:18 We have much better data. 53:19 We didn't have a way to handle on coronary inflammation before. 53:23 So thanks for your question. 53:24 Now, I just want to say we're really grateful for all of you here to be in attendance. 53:31 To be interactive with us. 53:33 We've had almost half the session getting some great questions from the group. 53:37 We've had a lot of people that are watching and listening from afar. 53:43 And we'll also be posting this. 53:45 And usually we get a couple hundred thousand people to view these. 53:50 So the person who I'm especially grateful for is Jo because she didn't know any of the questions I was going to ask her. 53:58 She didn't even impress me like some people do. 54:01 Tell me, what are you going to ask? 54:03 I hope it wasn't too tough or invasive, but it was great to learn more about you. 54:09 I had to study you before we did this interview to know all the things that a lot of people don't know. 54:15 She is a very unique We're all unique, but she is just an extraordinary person who I feel such a privilege to now know and think of as a friend. 54:25 And I hope you know Joe better after today. 54:28 So thank you, Joe. 54:29 Thank you. 54:32 Thank you. 54:35 [music] 55:15 ... ... ... 55:16 [music]
Community discussion